\n\n\u00a0<\/p><\/td> | \nThree Months Ended\nJune 30,<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \nSix Months Ended\nJune 30,<\/b><\/p><\/td><\/tr>\n\n\n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nRevenues:<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nProduct revenues, net<\/p><\/td> | \n$<\/p><\/td> | \n3,333.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,944.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n6,320.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n5,704.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nOther revenues<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n20.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n30.7<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nTotal revenues<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3,333.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,964.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n6,320.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n5,734.9<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nCosts and expenses:<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nCost of sales<\/p><\/td> | \n\u00a0<\/p><\/td> | \n489.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n407.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n882.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n770.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nResearch and development expenses<\/p><\/td> | \n\u00a0<\/p><\/td> | \n993.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n978.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,955.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,958.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nAcquired in-process research and development expenses<\/p><\/td> | \n\u00a0<\/p><\/td> | \n21.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n21.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n22.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nSelling, general and administrative expenses<\/p><\/td> | \n\u00a0<\/p><\/td> | \n582.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n424.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,075.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n821.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nIntangible asset impairment charge<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n379.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nChange in fair value of contingent consideration<\/p><\/td> | \n\u00a0<\/p><\/td> | \n0.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n0.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n0.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nTotal costs and expenses<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,087.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,813.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3,935.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3,953.7<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nIncome from operations<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,246.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,151.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,385.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,781.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nInterest income, net<\/p><\/td> | \n\u00a0<\/p><\/td> | \n120.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n118.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n235.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n236.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nOther income (expense), net<\/p><\/td> | \n\u00a0<\/p><\/td> | \n24.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n13.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n24.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(4.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nIncome before provision for income taxes<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,391.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n1,283.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,644.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,013.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nProvision for income taxes<\/p><\/td> | \n\u00a0<\/p><\/td> | \n292.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n250.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n513.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n334.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nNet income<\/p><\/td> | \n$<\/p><\/td> | \n1,099.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,032.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,131.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,679.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nNet income per common share:<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nBasic<\/p><\/td> | \n$<\/p><\/td> | \n4.34<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n4.02<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n8.39<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n6.54<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nDiluted<\/p><\/td> | \n$<\/p><\/td> | \n4.31<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n3.99<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n8.33<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n6.48<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nShares used in per share calculations:<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nBasic<\/p><\/td> | \n\u00a0<\/p><\/td> | \n253.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n256.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n253.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n256.8<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nDiluted<\/p><\/td> | \n\u00a0<\/p><\/td> | \n255.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n258.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n255.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n259.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n<\/table> \n\n\nVertex Pharmaceuticals Incorporated<\/b><\/p><\/td><\/tr>\n\n\nTotal Revenues<\/b><\/p><\/td><\/tr>\n\n\n(unaudited, in millions)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n\n\u00a0<\/p><\/td> | \nThree Months Ended\nJune 30,<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \nSix Months Ended\nJune 30,<\/b><\/p><\/td><\/tr>\n\n\n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td><\/tr>\n\n\nTRIKAFTA\/KAFTRIO<\/p><\/td> | \n$<\/p><\/td> | \n2,497.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,551.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n4,851.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n5,086.6<\/p><\/td><\/tr>\n | \n\nALYFTREK<\/p><\/td> | \n\u00a0<\/p><\/td> | \n573.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n156.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n998.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n210.7<\/p><\/td><\/tr>\n | \n\nOther CF product revenues (1)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n137.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n193.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n273.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n349.0<\/p><\/td><\/tr>\n | \n\nTotal CF product revenues, net<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3,207.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,901.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n6,122.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n5,646.3<\/p><\/td><\/tr>\n | \n\nCASGEVY<\/p><\/td> | \n\u00a0<\/p><\/td> | \n76.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n30.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n119.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n44.6<\/p><\/td><\/tr>\n | \n\nJOURNAVX<\/p><\/td> | \n\u00a0<\/p><\/td> | \n49.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n12.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n78.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n13.3<\/p><\/td><\/tr>\n | \n\nProduct revenues, net<\/p><\/td> | \n\u00a0<\/p><\/td> | \n3,333.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2,944.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n6,320.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n5,704.2<\/p><\/td><\/tr>\n | \n\nOther revenues<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n20.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u2014<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n30.7<\/p><\/td><\/tr>\n | \n\nTotal revenues<\/p><\/td> | \n$<\/p><\/td> | \n3,333.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,964.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n6,320.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n5,734.9<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n1: <\/b>Includes KALYDECO, ORKAMBI, and SYMDEKO\/SYMKEVI<\/p><\/td><\/tr>\n<\/table>\n\n\nVertex Pharmaceuticals Incorporated<\/b><\/p><\/td><\/tr>\n\n\nReconciliation of GAAP to Non-GAAP Financial Information<\/b><\/p><\/td><\/tr>\n\n\n(unaudited, in millions, except percentages)<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n\n\u00a0<\/p><\/td> | \nThree Months Ended\nJune 30,<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \nSix Months Ended\nJune 30,<\/b><\/p><\/td><\/tr>\n\n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2026<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n2025<\/b><\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nGAAP cost of sales<\/b><\/p><\/td> | \n$<\/p><\/td> | \n489.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n407.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n882.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n770.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nStock-based compensation expense<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(3.8<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(2.5<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(7.0<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(5.1<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nIntangible asset amortization expense<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(5.1<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(5.1<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(10.1<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(10.1<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nNon-GAAP cost of sales<\/b><\/p><\/td> | \n$<\/p><\/td> | \n480.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n399.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n864.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n755.3<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nGAAP research and development expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n993.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n978.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,955.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,958.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nStock-based compensation expense<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(104.4<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(99.6<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(206.1<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(199.7<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nIntangible asset amortization expense<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(0.7<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(0.7<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(1.3<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(1.3<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nNon-GAAP research and development expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n888.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n878.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,748.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,757.1<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nAcquired in-process research and development expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n21.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n21.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n22.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nGAAP selling, general and administrative expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n582.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n424.6<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,075.9<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n821.0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nStock-based compensation expense<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(62.0<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(65.2<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(123.5<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(128.6<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\nNon-GAAP selling, general and administrative expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n520.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n359.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n952.4<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n692.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nCombined non-GAAP R&D, AIPR&D and SG&A expenses<\/b><\/p><\/td> | \n$<\/p><\/td> | \n1,430.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n1,239.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,722.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n2,471.5<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nGAAP other income (expense), net<\/b><\/p><\/td> | \n$<\/p><\/td> | \n24.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n13.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n24.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n(4.4<\/p><\/td> | \n)<\/p><\/td><\/tr>\n | \n\n(Increase) decrease in fair value of strategic investments<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(37.2<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(5.4<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n(35.2<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n9.6<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nNon-GAAP other (expense) income, net<\/b><\/p><\/td> | \n$<\/p><\/td> | \n(12.9<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n7.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n(10.9<\/p><\/td> | \n)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n5.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nGAAP provision for income taxes<\/b><\/p><\/td> | \n$<\/p><\/td> | \n292.0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n250.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n513.5<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n334.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nTax adjustments (2)<\/p><\/td> | \n\u00a0<\/p><\/td> | \n31.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n32.1<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n90.3<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n192.2<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\nNon-GAAP provision for income taxes<\/b><\/p><\/td> | \n$<\/p><\/td> | \n323.7<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n282.2<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n603.8<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n$<\/p><\/td> | \n526.4<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n\n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td><\/tr>\n | \n| \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \n | \u00a0<\/td>\n<\/tr>\n | \n\nGAAP effective tax rate<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n21.0<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n19.5<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n19.4<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n16.6<\/p><\/td> | \n%<\/p><\/td><\/tr>\n | \n\nNon-GAAP effective tax rate<\/b><\/p><\/td> | \n\u00a0<\/p><\/td> | \n21.1<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n19.4<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n20.4<\/p><\/td> | \n%<\/p><\/td> | \n\u00a0<\/p><\/td> | \n\u00a0<\/p><\/td> | \n19.1<\/p><\/td> | \n%<\/p><\/td><\/tr>\n<\/table> Contacts<\/b> \nVertex Pharmaceuticals Incorporated<\/b>Investors:<\/b>InvestorInfo@vrtx.com<\/a>or\n617-961-7163<\/p>\nMedia:<\/b>mediainfo@vrtx.com<\/a>or\nInternational: +44 20 3204 5275\nor\nU.S.: 617-341-6992<\/p> Read full story here <\/a>","protected":false},"excerpt":{"rendered":"\u2014 Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 \u2014
\n\u2014 Raising full-year revenue guidance to $13.1 billion to $13.2 billion \u2014
\n\u2014 Continued progress across research and development pipeline; povetacicept PDUFA date November…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-50358","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50358"}],"version-history":[{"count":2,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50358\/revisions"}],"predecessor-version":[{"id":50360,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/50358\/revisions\/50360"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | | | | | | | | | |
![](\"https:\/\/mms.businesswire.com\/media\/20260803535433\/en\/1093022\/5\/Vertex_Logo_colorRGB.jpg\"){kind=logo}
<\/a>